^
    Apply
    Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin (NCT00773344)
    Phase 1/2
    Bristol-Myers Squibb
    Completed
    Last update posted :
    11/04/2015
    Initiation :
    12/01/2005
    Primary completion :
    05/01/2009
    Completion :
    08/01/2009
    HER-2
    |
    HER-2 overexpression • HER-2 amplification
    |
    Herceptin (trastuzumab) • tanespimycin (BMS-722782)